MDRNA, Inc. Announces Full Repayment of GE Capital Debt

BOTHELL, WA, Jun 16 (MARKET WIRE) --
MDRNA, Inc. (NASDAQ: MRNA) announced today that it has repaid all of its
remaining debt to General Electric Capital Corporation (GECC) under the
January 2009 Loan and Security Agreement.

"I am pleased we have met our commitment to shareholders to eliminate the
Company's remaining term debt obligations prior to the start of the third
quarter," stated J. Michael French, President and CEO. "In less than five
months time, we retired a $5.5 million loan created to consolidate our GE
Capital leases. The repayment of this loan removes all liens on our
intellectual property, equipment and other assets, thus providing us
maximum flexibility in establishing broad target and therapeutic-based
pharma collaborations. By eliminating the remaining debt, we have
significantly strengthened our balance sheet, enabling us to further
capitalize on our strong science and broad intellectual property estate."

Mr. French added, "I would like to thank everyone on the MDRNA team for
their outstanding efforts in the successful completion of our corporate
restructuring and transition to a leading RNAi therapeutics company."

About MDRNA, Inc.

MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference
(RNAi). Our goal is to improve human health by combining novel RNAi-based
compounds and proprietary peptide- and liposomal-based drug delivery
technologies to provide superior therapeutic options. Our
multi-disciplinary portfolio of capabilities includes molecular biology,
cellular biology, formulation expertise, peptide and alkylated amino acid
chemistry, pharmacology, toxicology and bioinformatics. We are applying
this expertise to a single, integrated drug discovery platform that will
be the engine for our clinical pipeline and a versatile platform for
establishing broad therapeutic partnerships. We are also building on new
technologies, such as UsiRNAs that incorporate the non-nucleotide moiety
Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that we
expect to lead to safer and more effective RNAi-based therapeutics. By
combining broad expertise in siRNA science with proven delivery platforms
and a strong and growing IP position, MDRNA is well positioned as a
leading RNAi therapeutics company and value-added collaborator for our
research partners. Additional information about MDRNA, Inc. is available
at http://www.mdrnainc.com.

MDRNA Forward-Looking Statements

Statements made in this news release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results
to differ materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of MDRNA to
obtain additional funding; (ii) the ability of MDRNA to attract and/or
maintain manufacturing, research, development and commercialization
partners; (iii) the ability of MDRNA and/or a partner to successfully
complete product research and development, including preclinical and
clinical studies and commercialization; (iv) the ability of MDRNA and/or a
partner to obtain required governmental approvals; and (v) the ability of
MDRNA and/or a partner to develop and commercialize products that can
compete favorably with those of competitors. Additional factors that could
cause actual results to differ materially from those projected or
suggested in any forward-looking statements are contained in MDRNA's most
recent periodic reports on Form 10-K and Form 10-Q that are filed with the
Securities and Exchange Commission. MDRNA assumes no obligation to update
and supplement forward-looking statements because of subsequent events.

Contacts:

Matthew D. Haines
Senior Director, Investor Relations and Corporate Communications
(212) 209-3874
Email Contact

McKinney|Chicago (Media)
Alan Zachary
(312) 944-6784 x 316 or
(708) 707-6834
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-